Numis Securities Ltd Reiterates Buy Rating for Clinigen Group PLC (CLIN)
Clinigen Group PLC (LON:CLIN)‘s stock had its “buy” rating restated by analysts at Numis Securities Ltd in a research report issued to clients and investors on Friday. They currently have a GBX 650 ($11.15) target price on the stock. Numis Securities Ltd’s target price would suggest a potential upside of 70.13% from the company’s current price.
Separately, analysts at Investec upgraded shares of Clinigen Group PLC to a “buy” rating in a research note on Monday. They now have a GBX 497 ($8.52) price target on the stock, down previously from GBX 560 ($9.61).
Clinigen Group PLC (LON:CLIN) traded up 0.72% during mid-day trading on Friday, hitting GBX 386.26. The stock had a trading volume of 23,319 shares. Clinigen Group PLC has a 52 week low of GBX 316.50 and a 52 week high of GBX 690.00. The stock has a 50-day moving average of GBX 413.3 and a 200-day moving average of GBX 514.7.
Clinigen Group plc (LON:CLIN) is a specialty pharmaceuticals and services business company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.